Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical […]

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units (CRUs) in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin.

“The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data,” said Oren Cohen, M.D., Fortrea’s president of Clinical Pharmacology and chief medical officer. “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them.”

Facility enhancements following the completed expansion include Fortrea’s new CRU in Leeds as well as purpose-built rooms in Madison and Daytona designed for flexibility in executing complex early phase clinical studies. Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.

The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP pharmacies within them. This enables on-site manufacture of sterile and non-sterile drug product. The design of its GMP-compliant facilities provides safe handling and delivery of GMP-quality drug product for the unique demands of clinical pharmacology studies, focusing on efficiency and flexibility with the level of controls expected by regulatory authorities and sponsors.

Enhancements in science and technology include the addition of artificial intelligence-enabled programs that optimize bed space utilization and clinic scheduling, and the application of failure modes and effects analysis to de-risk study execution before a study begins. Following investments in data collection systems, all clinical pharmacology study data collected within Fortrea’s CRUs are input directly into a digital bedside data capture system, which can also be used as an efficient electronic data capture solution.

“I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen. “I’m so proud of this team and know they will also benefit from the changes we have made. Just as they are inspired by our mission of bringing life-changing treatments to patients faster, I’m inspired by their dedication each day as we deliver solutions to our customers.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the anticipated financial and other benefits, including, but not limited to, whether the investments at clinical research units in U.S. and U.K. will add capacity, improve therapeutic capabilities, enhance experience for study volunteers, speed development to later-phase trials and improve the integrity of data and whether the addition of artificial intelligence-enabled programs will optimize bed space utilization and clinic scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in Fortrea’s registration statement on Form 10 initially filed with the SEC on May 15, 2023 (as amended and further supplemented), Fortrea’s quarterly report on Form 10-Q filed with the SEC on August 14, 2023, and in Fortrea’s other filings with the SEC. These forward-looking statements are based on management’s current expectations and are subject to certain risks, uncertainty and changes in circumstances. Fortrea does not undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

Fortrea Contacts:

Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva@fortrea.com

GlobeNewswire Distribution ID 8971131

Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical […]

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units (CRUs) in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin.

“The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data,” said Oren Cohen, M.D., Fortrea’s president of Clinical Pharmacology and chief medical officer. “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them.”

Facility enhancements following the completed expansion include Fortrea’s new CRU in Leeds as well as purpose-built rooms in Madison and Daytona designed for flexibility in executing complex early phase clinical studies. Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.

The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP pharmacies within them. This enables on-site manufacture of sterile and non-sterile drug product. The design of its GMP-compliant facilities provides safe handling and delivery of GMP-quality drug product for the unique demands of clinical pharmacology studies, focusing on efficiency and flexibility with the level of controls expected by regulatory authorities and sponsors.

Enhancements in science and technology include the addition of artificial intelligence-enabled programs that optimize bed space utilization and clinic scheduling, and the application of failure modes and effects analysis to de-risk study execution before a study begins. Following investments in data collection systems, all clinical pharmacology study data collected within Fortrea’s CRUs are input directly into a digital bedside data capture system, which can also be used as an efficient electronic data capture solution.

“I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen. “I’m so proud of this team and know they will also benefit from the changes we have made. Just as they are inspired by our mission of bringing life-changing treatments to patients faster, I’m inspired by their dedication each day as we deliver solutions to our customers.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the anticipated financial and other benefits, including, but not limited to, whether the investments at clinical research units in U.S. and U.K. will add capacity, improve therapeutic capabilities, enhance experience for study volunteers, speed development to later-phase trials and improve the integrity of data and whether the addition of artificial intelligence-enabled programs will optimize bed space utilization and clinic scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in Fortrea’s registration statement on Form 10 initially filed with the SEC on May 15, 2023 (as amended and further supplemented), Fortrea’s quarterly report on Form 10-Q filed with the SEC on August 14, 2023, and in Fortrea’s other filings with the SEC. These forward-looking statements are based on management’s current expectations and are subject to certain risks, uncertainty and changes in circumstances. Fortrea does not undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

Fortrea Contacts:

Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva@fortrea.com

UK is Building Its Most Powerful AI Supercomputer to Date

The UK government plans to invest $273 million to create its most powerful supercomputer to date, named Isambard-AI.Upon activation, it is poised to secure a place among the world’s most powerful AI supercomputers. With a multitude of Nvidia superchip…

The UK government plans to invest $273 million to create its most powerful supercomputer to date, named Isambard-AI.

Upon activation, it is poised to secure a place among the world’s most powerful AI supercomputers. With a multitude of Nvidia superchips at its core, Isambard-AI will be capable of executing over 200 quadrillion calculations per second. It is expected to come to life in the summer of 2024 at the University of Bristol.

This supercomputer will be built with the aid of Hewlett Packard Enterprise (HP), which is famous for its laptops. It will be powered by over 5000 Nvidia’s GH200 Grace Hopper Superchips, which will allow it to achieve more than 21 exaflops of AI performance. This is equivalent to more than 21 quintillion floating-point operations per second, specifically for AI tasks such as training large language models.

The University of Bristol claims that this level of performance will make Isambard AI 10 times faster than the UK’s current fastest AI supercomputer. The computer will be housed in a self-cooled, self-contained data center at Bristol’s National Composites Center.

But that’s not all. Isambard AI will also be able to connect with other supercomputers in the UK to further increase its performance. Simon McIntosh-Smith of the University of Bristol says that this will make the supercomputer “one of the most powerful AI systems for open science anywhere” once it’s up and running.

News about this supercomputer came out at the UK’s AI Safety Summit which was attended by leaders from different countries around the world including the US. The meeting was called to discuss the potential risks of AI and how to address them.

Source: Pro Pakistani

Cash Hungry CDA Plans Another Auction to Cover Expenses

The Capital Development Authority (CDA) is likely to hold another auction to meet its expenditures. Despite fetching Rs. 12.9 billion in the four-day auction last month, it fell short of the civic authority’s expectations.During the previous auction, …

The Capital Development Authority (CDA) is likely to hold another auction to meet its expenditures. Despite fetching Rs. 12.9 billion in the four-day auction last month, it fell short of the civic authority’s expectations.

During the previous auction, CDA sold nine commercial plots, two residential, and 14 half-marla plots. Now, it is looking to earn more money by selling more plots.

Chairman CDA, Anwarul Haq, on Wednesday, directed the estate wing to compile an inventory of commercial plots. Although, there are approximately 50 commercial plots of various sizes available to be sold, the Chairman asked to prepare a list of up to 25 plots.

The meeting also deliberated over the sale of a four-acre plot for the construction of a five-star hotel. The meeting was informed that there are two such plots near the Marriot Hotel, which could potentially generate billions of rupees due to their prime location.

However, CDA can not put these plots up for auction without the approval of the federal government. Once the government grants approval, an auction will be held.

An official of the CDA estate wing told a local media outlet that one of the five-star hotel plots was included in the last auction as well. However, due to the lack of permission from the federal government, it was excluded from the list.

The officer added that they have already written a letter to the government, seeking its permission to sell the plots. It should be noted that CDA is an autonomous entity, responsible for generating revenue to fund both its development and non-development expenses.

Along with its thousands of employees, it has to pay pensions and salaries too, and it also spends billions of rupees on development projects in Islamabad. However, due to financial constraints, it had suspended new development projects last month.

Source: Pro Pakistani

You Can Now Get Exclusive Front-Row Seats for Burj Khalifa New Year’s Eve Fireworks

Every year, thousands of people from across the globe travel to Dubai to celebrate the new year’s eve. The fireworks show at the Burj Khalifa has been one of the main attractions for the last few years.The New Year celebration at the world’s tallest t…

Every year, thousands of people from across the globe travel to Dubai to celebrate the new year’s eve. The fireworks show at the Burj Khalifa has been one of the main attractions for the last few years.

The New Year celebration at the world’s tallest tower is managed by the Emaar Properties. This time, they have decided to introduce a paid front-row-seat experience of the Burj Khalifa’s fireworks show at the Burj Park.

It is important to note that tourists can still witness the fireworks show for free but the paid facility has been introduced for those who want to get a better experience.

As far as ticket prices are concerned, adults will have to pay Dh300, while kids aged between 5 and 12 can get their tickets for Dh150. There is no entry fee for kids below the age of 5.

Tickets will be available on Platinumlist from November 10. Ticket holders must collect their badges from the Dubai Mall, Dubai Hills Mall, and Dubai Marina Mall on December 26 -30, from 2 pm to 10 pm.

Without the badge, no one will be allowed to enter Burj Park and access some specific areas. Ticket holders can also enjoy one free meal and two drinks at the food stalls.

The doors of Burj park will be opened at 4pm, which will feature food trucks, stalls, live performances, and more.

Source: Pro Pakistani

Competition Commission of Pakistan Appoints 4th Member

Saeed Ahmad Nawaz has joined the Competition Commission of Pakistan (CCP) as its fourth Member. He brings a wealth of experience to CCP.Saeed Ahmad Nawaz holds an MBA from the University of the Punjab with a specialization in finance. He earned the hi…

Saeed Ahmad Nawaz has joined the Competition Commission of Pakistan (CCP) as its fourth Member. He brings a wealth of experience to CCP.

Saeed Ahmad Nawaz holds an MBA from the University of the Punjab with a specialization in finance. He earned the highly competitive Hubert H. Humphrey Fellowship in 2002-03, where he studied finance and economics at Boston University in the USA.

Nawaz was awarded the World Bank-Government of Pakistan-sponsored Professional Development Program Award in 2006-07. He completed his M.Sc. in Local Economic Development from the London School of Economics, UK, expanding his academic horizons and engaging with public and private sector organizations in the US and the UK.

Saeed Ahmad Nawaz commenced his professional journey as a commissioned officer in the Pakistan Army and was inducted into the District Management Group. He has served in various capacities for the Governments of Punjab and KPK, from sub-divisions to provincial departments. His diverse roles included team leadership and staff officer positions.

At the National School of Public Policy, he served as Directing Staff, Chief Instructor, and Head of Administration (Director General). During his service in the Federal Secretariat, he successfully handled a spectrum of critical issues, including Covid-19 related relief measures, industrial policy, corporate governance, poverty alleviation, and social security.

Source: Pro Pakistani

Caretaker PM Anwar ul Haq Kakar Meets Shahid Afridi

Caretaker Prime Minister of Pakistan, Anwar ul Haq Kakar, met with former captain of the Pakistan team, Shahid Afridi.According to sources PM Anwar ul Haq Kakar and Shahid Afridi met in Islamabad.In the meeting, the PM of Pakistan appreciated Shahid A…

Caretaker Prime Minister of Pakistan, Anwar ul Haq Kakar, met with former captain of the Pakistan team, Shahid Afridi.

According to sources PM Anwar ul Haq Kakar and Shahid Afridi met in Islamabad.

In the meeting, the PM of Pakistan appreciated Shahid Afridi’s services to cricket in Pakistan.

In a conversation with Shahid Afridi, the Prime Minister of Pakistan requested him to actively participate on the field in order to contribute to the improvement of Pakistan’s cricket.

The PM said, “You are our legend, we want you to work for the betterment of Pakistan Cricket.”

He added, “You have given Pakistan cricket a lot of happiness; I want you to improve Pakistan cricket from grass root level.”

It should be noted that Shahid Afridi recently strongly criticized PCB Chairman Zaka Ashraf for his ineffective work and the team’s poor performance.

Shahid Afridi has also expressed his support for Pakistan’s captain, Babar Azam, who has been facing criticism during the ongoing World Cup 2023. Afridi believes that we should stand by him during this challenging period, as Babar is deeply committed to Pakistan cricket and is determined to bring about changes in the entire management staff of the Pakistan team.

Source: Pro Pakistani

Saudi Arabia to Offer Visa Facility for Pakistani IT Companies

Ambassador of the Kingdom of Saudi Arabia to Pakistan Nawaf bin Said Al-Malki on Thursday said that the Kingdom of Saudi Arabia will provide full support in facilitating visas for Pakistani IT companies.This was claimed by the Ministry of Information …

Ambassador of the Kingdom of Saudi Arabia to Pakistan Nawaf bin Said Al-Malki on Thursday said that the Kingdom of Saudi Arabia will provide full support in facilitating visas for Pakistani IT companies.

This was claimed by the Ministry of Information Technology and Telecommunication after a meeting between the Ambassador and Caretaker Federal Minister for IT and Telecommunication Dr. Umar Saif here on Thursday. Facilitation of Visas by Saudi Arabia for Pakistani IT professionals and business persons was specifically discussed during the meeting.

The official stated that matters of mutual interest and related to IT and Telecommunication were discussed during the meeting.

The two sides agreed to enhance cooperation in the IT and telecom sectors between the two countries.

Dr. Umar Saif said that the government of Pakistan wanted to boost relations with Saudi Arabia in the IT and telecom sectors. Saudi Arabia is a very attractive market for Pakistani IT companies, he said. He remarked that as Pakistani IT companies scale up their presence and businesses in Saudi Arabia, it’s important to facilitate their travel and Visas.

The IT minister said that there was great potential in IT and Telecom professionals in Pakistan. He went on to say that the environment for investment in Pakistan was conducive, urging the Saudi tech companies to invest in Pakistan.

Saudi Ambassador Nawaf bin Said Al-Malki added that Saudi Arabia will fully cooperate with Pakistan in the sector of IT and Telecom. The ambassador also ensured that the Kingdom of Saudi Arabia would provide full support in facilitating visas for Pakistani IT companies.

The meeting was attended by senior officers of the Ministry.

Source: Pro Pakistani